Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Foscarnet sodium
Drug ID BADD_D00964
Description An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Indications and Usage For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Marketing Status approved
ATC Code J05AD01
DrugBank ID DB00529
KEGG ID D00579
MeSH ID D017245
PubChem ID 44561
TTD Drug ID D0OT0O
NDC Product Code 29902-0018; 76310-024; 61662-0001; 70600-020; 59651-476; 68083-389; 63323-875; 23155-771; 79290-0001; 25021-189
UNII 964YS0OOG1
Synonyms Foscarnet | Phosphonoformic Acid | Foscarnet Trisodium Salt | Foscarnet Calcium (2:3) Salt | Foscarnet Disodium Salt | Foscarnet Magnesium (2:3) Salt | Trisodium Phosphonoformate | Phosphonoformate | Foscarnet Sodium | Foscarnet Trilithium Salt | Foscarnet Tripotassium Salt | Foscarnet Sodium Hexahydrate | Foscavir | Foscarnet Barium (2:3) Salt | Foscarnet Manganese (2+) (2:3) Salt
Chemical Information
Molecular Formula CNa3O5P
CAS Registry Number 63585-09-1
SMILES C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Meningitis17.06.03.001; 11.01.03.001--
Mouth ulceration07.05.06.004--Not Available
Muscle contractions involuntary15.05.03.008; 17.05.03.001--Not Available
Muscle disorder15.05.03.014--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myopathy15.05.05.001--Not Available
Myositis15.05.01.001--
Nausea07.01.07.001--
Nephrogenic diabetes insipidus14.05.07.002; 20.05.03.010--Not Available
Nephrolithiasis20.04.01.002--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutrophil count13.01.06.046--Not Available
Neutrophil count decreased13.01.06.010--
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Platelet count13.01.04.011--Not Available
Platelet disorder01.08.03.001--Not Available
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumothorax22.05.02.003--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages